|

Psychedelic Business News Spotlight: January 22, 2021

Psychedelic Business News Spotlight: January 22, 2021

This week in psychedelic business news: Canada’s NEO exchange gets the world’s first ETF, Daniel Carcillo’s Wesana Health raises $4 million, Revive Health raises $20 million, and more.

Former Chicago Blackhawk left-winger Daniel Carcillo, has raised $4 million for his psychedelic life sciences company, Wesana Health. The capital will help the company bring on new talent, including former MMA fighter Ian McCall, as well as expand preclinical and clinical trials.

Canada will have its first psychedelics-focused ETF. Trading begins next Wednesday. The Horizons Psychedelic Stock Index will focus on the emergent category treatment and research leaders. “After decades of restrictions, recent policy changes and exemptions in Canada and the United States have allowed for increased research in the therapeutic application of psychedelic compounds, and the potential to create an entirely new marketplace for drugs derived from psychedelics,” Steve Hawkins, President and CEO of Horizons ETFs, said in a statement.

Psychedelic drug developer Albert Labs, has signed a letter of intent to be acquired by ME Resource Corp.  Albert will be the first psychedelics company to use the Real World Evidence accelerated pathway in psychedelic treatment and research. 

 Mindset Pharma Inc., says it’s working on preparing its ‘next-gen’ psilocybin for clinical use. The new launch will be discussed later this month. According to the company, the new product is already pulling interest from larger psychedelic firms. 

Revive Therapeutics has increased its recent funding round from $10 million to $20 million. The psychedelic life sciences company is working on therapeutic uses of various substances in treating rare medical conditions. Funding comes from Canaccord Genuity Corp. and Leede Jones Gable Inc. to pay $0.50 per Equity Unit. The funding increase comes as Revive entered into a research agreement with North Carolina State University to develop a novel biosynthetic version of psilocybin.

Similar Posts

  • The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]

    Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
    It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
    We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
    We are going to do this because one, it’s a good article that I wanted to share with you
    And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.

    P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
    For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html

    Time Stamps
    0:00​ – Intro
    3:10 – Media Coverage on Tesla & Psychedelic Stocks
    6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
    8:05 – Influence on stock valuations and stealth investors
    10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​ #MindmedStock​​ #PsychedelicStocks

  • The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

    The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

    In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.

    I had a blast in this interview, and I know you will find it fascinating! Enjoy!

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

    #BrightMinds #PsychedelicStocks #Psilocybin